公开(公告)号：US20240252639A1

公开(公告)日：2024-08-01

申请号：US18562035

申请日：2022-04-14

申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

发明人： Michael VERNERIS ,  Jessica LAKE

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61P35/00 ,  C07K14/715 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K39/4631 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/464421 ,  A61K39/464429 ,  A61P35/00 ,  C07K14/7158 ,  C07K16/2827 ,  C12N5/0636 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/46 ,  C07K2317/622 ,  C12N2501/2308 ,  C12N2510/00

摘要： Embodiments relate to novel compositions and methods for treating solid tumors. Other embodiments relate to generating T cells able to home to and treat solid tumors. In accordance with these embodiments, T-cells expressing at least one C-X-C Motif Chemokine Receptor (CXCR) and chimeric antigen receptors (CARs) able to bind to B7H3 are disclosed. In certain embodiments, the present disclosure provides for polynucleotides and vectors encoding a CAR and a CXCR together or in separate constructs, where the CAR binds to B7H3 in solid tumor cells, other tumors, or malignancies. In other embodiments, methods of making T cells expressing a CAR that binds to B7H3 and expressing one or more CXCR are provided. In some embodiments, methods of preventing, treating, or ameliorating tumors or malignancies in a subject are disclosed including administering a composition of T cells expressing at least one CXCR and CARs that bind to B7H3.